Clinical trial of a drug for problems related to urination

Phase 2 clinical trials for assessment of safety and efficacy of a multi component therapeutic (SKBRADHA) in patients suffering from Urinary tract infection.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2017/11/010541

Enrollment

287

Registered

2017-11-17

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Patients suffering from Urinary tract infection

Interventions

Intervention1: SKBRADHA: Dose: 5 Gms Frequency: 5 times/day Route of administration: Oral Total duration of therapy: 8 days Control Intervention1: Placebo: Dose: 5 Gms Frequency: 5 times/day Route of

Eligibility

Inclusion criteria

Inclusion criteria: Patients suffering from Urinary tract infection

Exclusion criteria

Exclusion criteria: Healthy human volunteers

Design outcomes

Primary

Measure	Time frame
Complete freedom from symptoms of Urinary tract infection such as strong persistent urge to urinate, burning sensation, frequency of urination, pain, fever, strong smelling urine, cloudy urine, pink urine etc.Timepoint: 4 Hours	—

Secondary

Measure	Time frame
Complete freedom from symptoms of Urinary tract infection such as strong persistent urge to urinate, burning sensation, frequency of urination, pain, fever, strong smelling urine, cloudy urine, pink urine etc.Timepoint: 8 days	—

Countries

India

Contacts

Public ContactAshok Kumar

SK Biotherapeutics Pvt. Ltd. (Previously SK Biolabs)

ashok846@gmail.com8126688922

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026